Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment.
The use of decision-analytic modelling for the purpose of health technology assessment (HTA) has increased dramatically in recent years. Several guidelines for best practice have emerged in the literature; however, there is no agreed standard for what constitutes a 'good model' or how models should be formally assessed. The objective of this paper is to identify, review and consolidate existing guidelines on the use of decision-analytic modelling for the purpose of HTA and to develop a consistent framework against which the quality of models may be assessed. The review and resultant framework are summarised under the three key themes of Structure, Data and Consistency. 'Structural' aspects relate to the scope and mathematical structure of the model including the strategies under evaluation. Issues covered under the general heading of 'Data' include data identification methods and how uncertainty should be addressed. 'Consistency' relates to the overall quality of the model. The review of existing guidelines showed that although authors may provide a consistent message regarding some aspects of modelling, such as the need for transparency, they are contradictory in other areas. Particular areas of disagreement are how data should be incorporated into models and how uncertainty should be assessed. For the purpose of evaluation, the resultant framework is applied to a decision-analytic model developed as part of an appraisal for the National Institute for Health and Clinical Excellence (NICE) in the UK. As a further assessment, the review based on the framework is compared with an assessment provided by an independent experienced modeller not using the framework. It is hoped that the framework developed here may form part of the appraisals process for assessment bodies such as NICE and decision models submitted to peer review journals. However, given the speed with which decision-modelling methodology advances, there is a need for its continual update.
Philips
Zoë
Z
School of Economics, University of Nottingham, Nottingham, UK. Zoe.Philips@Nottingham.ac.uk
Bojke
Laura
L
Sculpher
Mark
M
Claxton
Karl
K
Golder
Su
S
D003362:Cost-Benefit Analysis; D003661:Decision Support Techniques; D006801:Humans; D016899:Interferon-beta / Q000191:economics / Q000627:therapeutic use; D018803:Models, Economic; D009103:Multiple Sclerosis / Q000188:drug therapy / Q000191:economics; D017410:Practice Guidelines as Topic; D013673:Technology Assessment, Biomedical / Q000379:methods*; D013997:Time Factors; D016896:Treatment Outcome; D035501:Uncertainty
D016899:Interferon-beta